SCHEMBL14840937

SCHEMBL14840937

Cc1nc(-c2ccncc2)c(C=O)s1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
CDC7 O00311 8/20 0.37
DBF4 Q9UBU7 8/20 0.37
CCNE1 P24864 2/20 0.37
CDK2 P24941 2/20 0.37
NTRK1 P04629 1/20 0.36
HPGD P15428 1/20 0.36
MAPK14 Q16539 2/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE3B Q13370 2/20 0.34
PDE3A Q14432 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PTGS2 P35354 1/20 0.33
CYP2A6 P11509 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10280665 0.84 NTRK1 (0.51) ALDH1A1NTRK1KMT2APTGDR2PTGS2
SCHEMBL14840640 0.78 CDK2 (0.35) CCNE1CDK2NTRK1MAPK14MAPK13
SCHEMBL8472083 0.76 ALDH1A1 (0.58) ALDH1A1CDC7DBF4CCNE1CDK2
SCHEMBL22650224 0.73 ALDH1A1 (0.39) ALDH1A1CDC7DBF4CCNE1CDK2
SCHEMBL12491028 0.73 ALDH1A1 (0.39) ALDH1A1CDC7DBF4CCNE1CDK2
SCHEMBL27544895 0.72 CDC7 (0.49) ALDH1A1CDC7DBF4CCNE1CDK2
SCHEMBL14840597 0.72 KDM4E (0.41) CDC7DBF4CCNE1CDK2MAPK14
SCHEMBL1884744 0.72 MAPT (0.57) ALDH1A1HPGDKMT2ASMN1; SMN2
SCHEMBL13494028 0.71 CDC7 (0.63) CDC7DBF4CCNE1CDK2NTRK1
SCHEMBL8468665 0.70 CDC7 (0.60) ALDH1A1CDC7DBF4CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-16 US disclosed
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2021-07-08 US disclosed
US-9440990-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-09-13 US disclosed
US-20150376205-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-31 US disclosed
US-8648079-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-11 US disclosed
US-20130090341-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376205-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, PSEN1, HTT ALDH1A1 59/4885CDC7 4687/4885DBF4 3385/4885
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 ALDH1A1 101/4885CDC7 4636/4885DBF4 3082/4885
US-20130090341-A1 HETEROCYCLIC COMPOUNDS HTT, NQO1, BDNF ALDH1A1 300/4885CDC7 3541/4885DBF4 1850/4885
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 ALDH1A1 101/4885CDC7 4636/4885DBF4 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.